REANDA-NEWS. July 03, 2015. Following on from the Company's successful European study, MIMICS-2 is a single-arm, multi-centre clinical trial of Veryan's BioMimics 3D® stent technology being conducted under US Investigational Device Exemption (IDE) approved by FDA. The study will enrol 280 subjects in up to 40 sites in the US and Germany and will evaluate the BioMimics 3D stent against performance goals for the safety and effectiveness of Nitinol stents used in the treatment of symptomatic disease of the femoropopliteal artery. The first subject was enrolled today at Universit?ts-Herzzentrum Freiburg in Bad Krozingen, Germany by the European Principal Investigator (PI), Professor Thomas Zeller, who was also the PI of Mimics, the company's previous randomized controlled study.

Veryan is Innovations' third largest portfolio company by value and as of 31 January 2015 the Group had a 48.2% interest in the Company with a fair value of 20.9 million.

Nigel Pitchford, Chief Investment Officer of Imperial Innovation said:

"Approval of the IDE and the commencement of the clinical trial is an important milestone for Veryan.

"We are excited by the prospect that MIMICS-2 study will provide further evidence that BioMimics 3D stent offers significant benefits in femoropopliteal use, ultimately leading to approval in the US, thereby expanding the market beyond its current European approval."